Inhibikase Therapeutics, Inc.
IKT
Positions held
Your positionsIKT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $266.51M | Enterprise value | $188.74M | Trailing P/E | — | Forward P/E | -4.42 |
| PEG | — | Price / book | 2.18 | Beta | 0.90 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -52.0% | ROA | -32.8% | Debt / equity | — |
| Current ratio | 15.82 | Free cash flow | -$22.10M | Analyst recommendation | none | Mean target | $6.00 |
| 52w high | $2.61 | 52w low | $1.33 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$19.6M | -$16.4M | -$12.7M | -$11.9M | -$9.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.1M | -$18.2M | -$13.1M | -$13.3M | -$11.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$53.3M | -$28.6M | -$20.1M | -$18.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 · Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-07-23 · Inhibikase Therapeutics Wins US FDA Orphan Drug Status for IKT-001 in Pulmonary Arterial Hypertension
2026-07-23 · Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-14 · Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Price (daily)
Full chart · RSI · MACD · patterns